Frontier Biotechnologies

Frontier Biotechnologies Inventory

The Inventory of Frontier Biotechnologies (688221.SS) as of Nov 5, 2026 is 66.62 M CNY. In the previous year, Inventory was 41.06 M CNY — a change of 62.25% (higher).

Inventory

66.62 MCNY

YoY

62.25%

Last updated:

Inventory of Frontier Biotechnologies is 2025 66.62 M CNY. Inventory of Frontier Biotechnologies was 2024 41.06 M CNY. It decreases by 62.25% higher compared to the previous year.

The Frontier Biotechnologies Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
12.20 M CNY
Jan 1, 2019
19.47 M CNY
Jan 1, 2020
13.53 M CNY
Jan 1, 2021
38.62 M CNY
Jan 1, 2022
55.61 M CNY
Jan 1, 2023
59.00 M CNY
Jan 1, 2024
41.06 M CNY
Jan 1, 2025
66.62 M CNY
The Frontier Biotechnologies Inventory history
YEARInventoryYoY
66.62 MCNY+62.25%
41.06 MCNY-30.41%
59.00 MCNY+6.10%
55.61 MCNY+44.00%
38.62 MCNY+185.43%
13.53 MCNY-30.51%
19.47 MCNY+59.59%
12.20 MCNY+1,425.00%
800,000.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Frontier Biotechnologies Stock analysis

What does Frontier Biotechnologies do? Frontier Biotechnologies, Inc. develops and sells medicines through its product portfolio, including Aikening and the Combination regiment of Albuvirtide (ABT) + 3BNC117, which is in clinical stage for HIV treatment. The company also offers transdermal analgesic patch AB001 for muscle, skeleton, and joint pain, currently in clinical development. Frontier Biotechnologies operates within the China market and serves overseas markets with its pharmaceutical products. The company generates revenue primarily from the research, development, and sale of its clinical-stage medicines, targeting both domestic and international healthcare providers and distributors. Its products are positioned for treatment of HIV and pain management, with AB001 focusing on non-invasive pain relief solutions. Frontier Biotechnologies focuses on advancing its pipeline through clinical trials to bring these therapies to market. Frontier Biotechnologies, Inc. is a biotechnology firm headquartered in Nanjing, Jiangsu, with 495 full-time employees. It conducts its business activities in China and overseas, leveraging its R&D capabilities to develop innovative treatments for unmet medical needs. The firm's revenue streams are derived from the commercialization of its pipeline products once they reach the market. Frontier Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Frontier Biotechnologies stock

Inventory of Frontier Biotechnologies is 66.62 M CNY in 2025.

Inventory of Frontier Biotechnologies changed from 41.06 M CNY to 66.62 M CNY, representing a 62.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Frontier Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Frontier Biotechnologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Frontier Biotechnologies

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Frontier Biotechnologies